In connection with the start of the phase 3 trials of PCV21, Sanofi has expanded its alliance with South Korea-based SK Bio, ...

SK bioscience and Sanofi have expanded their agreement to jointly develop pneumococcal conjugate vaccines (PCVs) targeting ...

Sanofi SNY and its partner SK bioscience announced that they have expanded their agreement to develop, license and ...

SK Bioscience and global pharmaceutical giant Sanofi signed an expanded agreement to jointly develop next-generation ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...

SK Bioscience, Sanofi collaborate on next-gen pneumococcal vaccine development SK Bioscience and Sanofi join forces to ...

In this cluster-randomized controlled trial, it was found that a pneumococcal conjugate vaccine (PCV) schedule involving a ...

South Korean pharmaceutical company SK Bioscience said Monday that it has joined forces with French drugmaker Sanofi to ...

French pharma major Sanofi says it has entered into a new chapter of the collaboration with South Korean firm SK bioscience ...

The following is a summary of “Evaluating Sex Differences in Pneumococcal Disease Burden and Vaccination Effectiveness in ...

is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter phase 3 in infants & toddlers Paris, December 23, 2024. Sanofi and SK bioscience have entered into a new ...

Inequalities in childhood vaccination are widening in England, with uptake rates of five key vaccines consistently lower in ...